In this issue:
Erlotinib then cisplatin/gemcitabine in advanced NSCLC
Gefitinib or erlotinib and CNS progression in EGFR-mutated NSCLC
ROS1 rearrangements in NSCLC
Preoperative 5FU/leucovorin for T3–4 rectal cancer
Family history increases lung cancer risk
Please login below to download this issue (PDF)